Investment Thesis
Septerna demonstrates exceptional revenue growth (4,174% YoY) suggesting successful product commercialization, but faces severe profitability challenges with negative operating margins (-50.1%) and negative operating cash flow (-$25.6M), indicating the business is not sustainable at current cost structures despite solid balance sheet reserves.
Strengths
- Extraordinary revenue growth of 4,174% YoY demonstrates strong market traction and successful product commercialization
- Fortress balance sheet with zero long-term debt, $71.6M cash, and 4.71x current ratio providing substantial runway
- Improving EPS trajectory (+84.8% YoY) suggesting margin compression is narrowing
Risks
- Severely negative operating cash flow (-$25.6M) against only $26.5M revenue indicates unsustainable burn rate and operational inefficiency
- Operating losses of $13.3M on $26.5M revenue (-50.1% margin) suggests structural cost challenges with manufacturing/operations
- Path to profitability unclear in highly competitive pharmaceutical sector; company must demonstrate ability to scale efficiently and achieve positive operating leverage
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Gross margin percentage and operating leverage improvements as revenue scales
- Cash runway duration given current burn rate and funding sustainability
Financial Metrics
Revenue
26.5M
Net Income
-8.6M
EPS (Diluted)
$-0.19
Free Cash Flow
-26.5M
Total Assets
569.7M
Cash
71.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-50.1%
Net Margin
-32.6%
ROE
-2.3%
ROA
-1.5%
FCF Margin
-99.8%
Balance Sheet & Liquidity
Current Ratio
4.71x
Quick Ratio
4.71x
Debt/Equity
0.00x
Debt/Assets
33.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:18:17.913581 |
Data as of: 2026-03-31 |
Powered by Claude AI